These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22247841)

  • 1. Novel drug delivery systems: desired feat for tuberculosis.
    Kaur K; Gupta A; Narang RK; Murthy RS
    J Adv Pharm Technol Res; 2010 Apr; 1(2):145-63. PubMed ID: 22247841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Drug-Sensitive and -Resistant Strains of Mycobacterium tuberculosis by Inhibition of Src Family Kinases Lowers Disease Burden and Pathology.
    Chandra P; Rajmani RS; Verma G; Bhavesh NS; Kumar D
    mSphere; 2016; 1(2):. PubMed ID: 27303736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ; Warner DF; Mizrahi V
    Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allicin enhances antimicrobial activity of macrophages during Mycobacterium tuberculosis infection.
    Dwivedi VP; Bhattacharya D; Singh M; Bhaskar A; Kumar S; Fatima S; Sobia P; Kaer LV; Das G
    J Ethnopharmacol; 2019 Oct; 243():111634. PubMed ID: 30537531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis drug targets.
    Zhang Y; Amzel LM
    Curr Drug Targets; 2002 Apr; 3(2):131-54. PubMed ID: 11958297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanocarrier-based interventions for the management of MDR/XDR-TB.
    Mustafa S; Pai RS; Singh G; Kusum Devi V
    J Drug Target; 2015 May; 23(4):287-304. PubMed ID: 25766078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
    Khusro A; Aarti C; Barbabosa-Pliego A; Salem AZM
    Microb Pathog; 2018 Jan; 114():80-89. PubMed ID: 29174699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies.
    Borah P; Deb PK; Venugopala KN; Al-Shar'i NA; Singh V; Deka S; Srivastava A; Tiwari V; Mailavaram RP
    Curr Top Med Chem; 2021; 21(6):547-570. PubMed ID: 33319660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
    Uddin R; Zahra NU; Azam SS
    Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
    Marimani M; Ahmad A; Duse A
    Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of resistance to anti-tuberculosis drugs in the clinical isolates of Mycobacterium tuberculosis from Slovakia through comparison between phenotypic and genetic methods and evaluation of resistance levels with clinical parameter.
    Mokry J; Porvaznik I; Kusnir P; Dohal M; Solovic I
    J Physiol Pharmacol; 2019 Feb; 70(1):. PubMed ID: 31172969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobactericidal activity of some micro-encapsulated synthetic Host Defense Peptides (HDP) by expediting the permeation of antibiotic: A new paradigm of drug delivery for tuberculosis.
    Sharma A; Vaghasiya K; Ray E; Gupta P; Kumar Singh A; Datta Gupta U; Kumar Verma R
    Int J Pharm; 2019 Mar; 558():231-241. PubMed ID: 30630076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis.
    Sheikh BA; Bhat BA; Mehraj U; Mir W; Hamadani S; Mir MA
    Curr Pharm Biotechnol; 2021; 22(4):480-500. PubMed ID: 32600226
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.